HomeList of TitleSearchContact Us

Open Journal of Hematology

ISSN: 2075-907X
Volume 8, 2017

Indexed in:

Open Journal of Hematology, 2014, 5-5 [Case Report]

Mogamulizumab for adult T-cell leukemia/lymphoma expressing atypical phenotype CD4-/CD8+/CCR4+

Hiroshi Ureshino1, Natsuko Komiya1, Eizaburo Sueoka2, Shinya Kimura2,*, Masaharu Miyahara1

1 Department of Internal Medicine, Karatsu Red Cross Hospital, Saga, Japan
2 Department of Internal Medicine, Saga University, Saga, Japan

Corresponding Author & Address:

Shinya Kimura*
Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, 5-1-1 Nabeshima, Saga 849-8501, Japan. TEL: +81-952-34-2353, FAX: +81-952-34-2017, Email: shkimu@cc.saga-u.ac.jp

Article History:
Published: 23rd June, 2014   Accepted: 23rd June, 2014
Received: 9th March, 2014      

© Kimura et al.; licensee Ross Science Publishers

ROSS Open Access articles will be distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided that the original work will always be cited properly.

Keywords: Mogamulizumab, CD4, CD8, CCR4, adult T-cell leukemia/lymphoma


Adult T-cell leukemia/lymphoma (ATL) cells are generally CD4+, CD8- and CCR4+. A 76-year-old man was diagnosed with a rare case of CD4-/CD8+ ATL in 2013. He was initially treated with the THP-COP regimen. The number of ATL cells in lymph nodes and peripheral blood (PB) and the level of soluble interleukin-2 receptor (sIL-2R) were decreased initially after chemotherapy but increased within 3 months and hypercalcemia appeared. Thus, the patient was diagnosed with ATL progression. Since CCR4 expression in CD4-/CD8+ ATL cells was confirmed by flow cytometry, the patient was treated with the newly developed CCR4 antibody mogamulizumab. Treatment significantly eradicated ATL cells in PB. To our knowledge, this is the first case of CD4- ATL treated with mogamulizumab.

©2017 Ross Science Publishers